A system comprising: a) a report that: i) provides a sample concentration of cTnI from a first, second, or third trimester for a pregnant woman as tested by an immunoassay; ii) indicates that the sample concentration of cTnI from said first, second, or third trimester is higher than a 99th percentile cTnI concentration from a corresponding first, second, or third trimester uncomplicated pregnancy control group as tested by the immunoassay, wherein the 99th percentile cTnI concentration for said first trimester is about 4.0 pg/ml, the 99th percentile cTnI concentration for said second trimester is about 4.0 pg/ml, and the 99th percentile cTnI concentration for said third trimester is about 6.0 pg/ml: and iii) indicates that said pregnant woman has, or is at risk of developing, cardiovascular disease or a complication of CVD; and b) a computer for generating said report, which computer comprises: i) a computer processor for receiving, processing, and communicating data, ii) a storage component for storing data which contains a reference database containing said 99th percentile cTnI concentration for said first, second, and third trimester uncomplicated pregnancy control groups; and iii) a computer program embedded within said computer processor, which is configured to process said sample concentration of cTnI in the context of said reference database to determine, as an outcome, if said pregnant woman has, or is at risk for developing, CVD or a complication of CVD. a) a report that: i) provides a sample concentration of cTnI from a first, second, or third trimester for a pregnant woman as tested by an immunoassay; ii) indicates that the sample concentration of cTnI from said first, second, or third trimester is higher than a 99th percentile cTnI concentration from a corresponding first, second, or third trimester uncomplicated pregnancy control group as tested by the immunoassay, wherein the 99th percentile cTnI concentration for said first trimester is about 4.0 pg/ml, the 99th percentile cTnI concentration for said second trimester is about 4.0 pg/ml, and the 99th percentile cTnI concentration for said third trimester is about 6.0 pg/ml: and iii) indicates that said pregnant woman has, or is at risk of developing, cardiovascular disease or a complication of CVD; and i) provides a sample concentration of cTnI from a first, second, or third trimester for a pregnant woman as tested by an immunoassay; ii) indicates that the sample concentration of cTnI from said first, second, or third trimester is higher than a 99th percentile cTnI concentration from a corresponding first, second, or third trimester uncomplicated pregnancy control group as tested by the immunoassay, wherein the 99th percentile cTnI concentration for said first trimester is about 4.0 pg/ml, the 99th percentile cTnI concentration for said second trimester is about 4.0 pg/ml, and the 99th percentile cTnI concentration for said third trimester is about 6.0 pg/ml: and iii) indicates that said pregnant woman has, or is at risk of developing, cardiovascular disease or a complication of CVD; and b) a computer for generating said report, which computer comprises: i) a computer processor for receiving, processing, and communicating data, ii) a storage component for storing data which contains a reference database containing said 99th percentile cTnI concentration for said first, second, and third trimester uncomplicated pregnancy control groups; and iii) a computer program embedded within said computer processor, which is configured to process said sample concentration of cTnI in the context of said reference database to determine, as an outcome, if said pregnant woman has, or is at risk for developing, CVD or a complication of CVD. i) a computer processor for receiving, processing, and communicating data, ii) a storage component for storing data which contains a reference database containing said 99th percentile cTnI concentration for said first, second, and third trimester uncomplicated pregnancy control groups; and iii) a computer program embedded within said computer processor, which is configured to process said sample concentration of cTnI in the context of said reference database to determine, as an outcome, if said pregnant woman has, or is at risk for developing, CVD or a complication of CVD.